

## Article

# A One-Step Grafting Methodology Can Adjust Stem Morphology and Increase THCA Yield in Medicinal Cannabis

Sarah Jane Purdy <sup>1,\*</sup>, Amitha K. Hewavitharana <sup>2</sup>, Razlin Azman Halimi <sup>2</sup> , Nelson Joel Magner <sup>1</sup>,  
Tyson James Peterswald <sup>1</sup>, Amy Trebilco <sup>1</sup>, Tobias Kretzschmar <sup>2</sup> and Deborah Hailstones <sup>3</sup> 

<sup>1</sup> New South Wales Department of Primary Industries, 105 Prince Street, Orange, NSW 2800, Australia; nelson.magner@dpi.nsw.gov.au (N.J.M.); tyson.peterswald@dpi.nsw.gov.au (T.J.P.); amy.trebilco@dpi.nsw.gov.au (A.T.)

<sup>2</sup> Southern Cross Plant Science, Southern Cross University, Military Rd, East Lismore, NSW 2480, Australia; ahewavitharana@pharmacy.uq.edu.au (A.K.H.); razlin.mohd.azman.halimi@scu.edu.au (R.A.H.); tobias.kretzschmar@scu.edu.au (T.K.)

<sup>3</sup> New South Wales Department of Primary Industries, Elizabeth Macarthur Agricultural Institute, Woodbridge Rd, Menangle, NSW 2568, Australia; deborah.hailstones@dpi.nsw.gov.au

\* Correspondence: sarah.purdy@dpi.nsw.gov.au



**Citation:** Purdy, S.J.; Hewavitharana, A.K.; Azman Halimi, R.; Magner, N.J.; Peterswald, T.J.; Trebilco, A.; Kretzschmar, T.; Hailstones, D. A One-Step Grafting Methodology Can Adjust Stem Morphology and Increase THCA Yield in Medicinal Cannabis. *Agronomy* **2022**, *12*, 852. <https://doi.org/10.3390/agronomy12040852>

Academic Editors: Antonios Chrysargyris, Helen D. Skaltsa and Maria Konstantopoulou

Received: 1 March 2022

Accepted: 25 March 2022

Published: 30 March 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** The standard two-step methods for grafting horticultural crops involve cultivating the rootstock for a period of time and then connecting the scion. Medicinal Cannabis differs from most annual horticultural crops because it is usually clonally propagated from cuttings. We developed a grafting methodology specifically for medicinal Cannabis, involving a single step, in which a freshly cut scion is grafted to a freshly cut donor stem that will become the rootstock. This study also aimed to uncover a potential role for roots in influencing cannabinoid content. Two varieties with desirable attributes but cultivation limitations were selected to act as scions. The first, “CBD1” was a high CBDA accumulating variety with low biomass yield, and the second, “THC2”, was a high yielding, high THCA accumulating line with inconsistent root development during cloning. Two candidate rootstocks, “THC9r” and “THC8r”, were identified; both were high THCA, low CBDA varieties. Biomass yields in the THC2 scions grafted to THC9 rootstocks (THC9r\_2s) were 20% higher than in the non-grafted THC2 plants. In CBD1 grafted plants, the concentrations of CBDA and some minor cannabinoids were significantly different to non-grafted CBD1, but biomass yields were lower. There was a trend towards a higher concentration of THCA in THC9r\_2s plants, and when combined with the increased biomass, yield of THCA was increased from 8 g Plant<sup>-1</sup> to 13 g Plant<sup>-1</sup>. Our results present a new grafting method for medicinal Cannabis that improved yield in THC2 and required no additional cultivation time.

**Keywords:** medicinal Cannabis; agronomy; cannabinoids; grafting; THC; CBD

## 1. Introduction

Medicinal Cannabis (*Cannabis sativa*) is a new crop to Australia with licenced cultivation approved as recently as 2016 [1]. In 2021, the Australian Government's Department of Health, Office of Drug Control (ODC), listed 48 companies and organisations that had been granted licenses to cultivate and produce medicinal Cannabis [2]. There is a demand for new and improved agronomic cultivation practices to protect and maximise yields and consequently profit margins for this growing industry.

Medicinal Cannabis is cultivated for its terpenophenolic phytocannabinoids, which interact with a mammalian neuronal signalling pathway, the endocannabinoid system [3,4]. Over 140 cannabinoids have been identified from Cannabis, but the two main targets for medicinal cultivation are  $\Delta^9$ -tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) [5–7]. These secondary metabolites when decarboxylated to their neutral

forms of  $\Delta^9$ -tetrahydrocannabinol (THC) and cannabidiol (CBD) are used for the treatment of non-communicable diseases including multiple sclerosis, childhood epilepsy, appetite stimulation, and sleep disorders [8–12]. Recently, cannabigerolic acid (CBGA) and cannabigerovarinic acid (CBGVA) have been shown to have anticonvulsant effects in epilepsy mouse models [7]. These cannabinoids were bioactive in their acidic forms that are usually decarboxylated during the heating processes used to manufacture Cannabis therapeutics [7]. They are also considered minor cannabinoids as they are found in significantly lower abundance than THCA and CBDA. Based on this recent finding, it is likely that minor cannabinoids may gain importance as target compounds as clinical and pharmacological research further advances.

Commercial yields of medicinal Cannabis are usually cited as being measured in g dry flower  $m^2$  (or equivalent imperial units) [13–15]. Therefore, as with any commercial crop, biomass yield is critical to productivity. However, as medicinal Cannabis is harvested for its cannabinoids, a high concentration of target metabolite g dry flower (eg % CBDA or THCA) is also essential. The unit of  $m^2$  relates to plant density within the growing environment and is therefore a product of infrastructure (e.g., fertigation design, bench ergonomics) and the morphology of the plants (e.g., height, lateral branch number and angle, floral structure). A unit of time is unaccounted for in the cited calculation, but most commercial growers will aim for >5 cycles of production in a 12-month period, so the speed of maturation is also important. The combination of biomass yield, cannabinoid concentration, plant density, and cycle time offers four different ways in which yield can be targeted for improvement.

Grafting is an ancient technique routinely applied for the improvement of horticultural crops including perennial fruit trees and vines, such as citrus and grape, and annuals including tomatoes, watermelon, and capsicum [16]. It is used globally and extensively, for example, in Korea, an area of more than 23,000 ha was used to cultivate watermelon in 2005 and of these >90% were grafted; in the Netherlands, 75% of commercial tomato plants are grafted [17]. The benefits of grafting include yield increase, abiotic stress tolerance, biotic stress resistance, quality changes, modified stem architecture, and improved water use efficiency [17,18].

Grafting involves the selection of at least two plants, one to provide the rootstock and the other the harvested above-ground growth, the scion. The grafting process connects the sections, resulting in a conjoined vascular system [19]. Most annual glasshouse crops are grown from seed. The seeds for both plant organs (root and shoot) are germinated, often with staggered timing to ensure that both sections are the optimal size when the graft is made. For example, watermelon seeds that will form a scion are sown 7–8 days after the sowing of the rootstock seeds, and then, grafting takes place a further 7–8 days after the scion germination [17]. The process of grafting can be summarised in four steps: (1) rootstock and scion selection and production, (2) joining of the two sections through wounding to form a union, (3) fusing of the union, and (4) acclimation of the grafted plant [17].

Medicinal Cannabis differs from most annual crops cultivated under protected cropping because plants are usually clonally propagated rather than grown from seed. This is because Cannabis is a highly heterozygous, dioecious (and therefore an obligate out-crossing) species that does not produce true-to-type progeny and only the unfertilised female plants produce the prime cannabinoid-laden flowers. Clonal propagation thus removes the risk of producing male plants and ensures a genetically uniform crop. Clones are generated from mother plants that are maintained in a vegetative (non-flowering) state [20]. New clones are excised from the mother plants, placed into a propagation medium, and maintained under controlled humidity until roots form, and the clone can transition to vegetative growth [20]. In order to apply grafting to medicinal Cannabis without adapting commercial propagation procedures, both the rootstock and the scion would need to be clonally propagated from vegetative tissue rather than heterozygous seeds. The greatest cost to production for Australian medicinal Cannabis is labour, which accounts for ~46% of

production costs [21]. Therefore, any proposed new cultivation methodology must balance the yield benefit against any additional labour requirements.

We aimed to develop a grafting methodology specifically for medicinal Cannabis that utilized clonal propagation for both rootstock and scion. The method had to require minimal manual handling to keep labour costs down and confer a yield and or/cultivation advantage.

We aimed to improve performance of two commercial lines through grafting. The first, “CBD1”, is a high CBDA accumulating cultivar but exhibits a low flower biomass yield. The second, “THC2”, is a tall, high yielding, high THCA accumulating line that exhibits highly variable root development and therefore results in a high clonal failure rate and inconsistent plant yield performance.

A number of environmental, abiotic, and biotic factors have been cited as affecting cannabinoid content and/or profile [22]. They include nitrogen fertilization rates [23], light spectrum [24–26], pruning [27], and drought [28]. Conversely, however, a number of studies have found little or no impact on cannabinoids of treatments such as flooding, wounding, botrytis infection as a growth regulator [29], or blue light [30]. It is currently unknown what role, if any, the root plays in determining the cannabinoid profile. This study aimed to identify root effects on the cannabinoid profile by grafting plants with diverse chemotypes and/or morphology.

## 2. Materials and Methods

### 2.1. Plant Material

Eight medicinal Cannabis genotypes were supplied from Cann Group Ltd. The eight varieties are presented in Table 1. They comprised of one high CBDA producing line and seven high THCA lines.

**Table 1.** Description of germplasm used.

Variety	Chemotype	Rootstock or Scion	Experiment
CBD1	High CBD	Scion	1–4
THC1	High THC	Rootstock	3
THC2	High THC	Rootstock and Scion	3,4
THC3	High THC	Rootstock	3
THC6	High THC	Rootstock	3
THC7	High THC	Rootstock	1–3
THC8	High THC	Rootstock	3,4
THC9	High THC	Rootstock	3,4

All plants were cultivated in an ODC approved secure glasshouse facility. All experiments were conducted under a Commonwealth license and associated permits. The temperature was maintained at 25 °C and humidity at 50%. Plants were grown under natural light with supplementary lighting (Heliospectra, Elixia LX6xx, C-Plate, heliospectra.com, 20 March 2022) to extend the photoperiod of vegetative plants. Blackout curtains were used to shorten the photoperiod for flowering plants. Water and nutrients were supplied by a fertigation system. The curtain, climate, and fertigation systems were automated (Priva, priva.com, 20 March 2022).

Experimental plants were cloned from donor mothers. New growth stems of approximately 15 cm were excised from the mother. All leaves up the sides of the stem were removed, leaving the top leaf bunch. The bottom of the stem was then cut diagonally across a node using a scalpel, to form a clone approximately 12 cm in height. The top leaf bunch was trimmed to the height of the smallest emerging leaf to reduce water loss and prevent the clones from overlapping in the propagation dome. The bottom 1 cm of the stem, from which the roots would form, were lightly scraped with a scalpel and then dipped in hormone gel (Clonex Purple, Yates, DuluxGroup, Canterbury-Bankstown, VA, 3169, Australia) and placed in an organic propagation cube (Eazyplug CT12, The Netherlands, <https://www.eazyplug.nl/>, accessed on 20 March 2022). Once the propagation tray

was full of new clones, it was placed in a propagation dome (Smart Garden heavy duty 3-piece propagation kit, Epping Hydroponics) for 2 weeks under an 18 h light: 6 h dark (18L:6D) photoperiod in a growth cabinet (Convion A2000, <https://www.convion.com>, accessed on 20 March 2022) at a light intensity of  $100 \mu\text{Mol m}^{-2} \text{s}^{-1}$  and a temperature of  $25 \text{ }^{\circ}\text{C}$ . Humidity monitors were placed in a dome and the humidity was progressively reduced over the fourteen-day propagation period. Plants with established roots were then potted into 1 l pots containing a 30:70% blend of perlite and coco-coir (Professors Nutrients, <https://www.professorsnutrients.com.au>, accessed on 20 March 2022); vegetative growth was fourteen days (except for experiment 3, detailed below) under glasshouse conditions. At the end of the fourteen-day period of vegetative growth, plants that were used in flowering experiments were repotted into 9 L flowering pots containing a 30:70% perlite: coco-coir blend and transferred to the flowering zone in which daylength was reduced to a 12L:12D photoperiod.

All trials were conducted on spaced plants to maximize light penetration and eliminate the risk of shading. Vegetative growth trials followed a fully randomized design on a single bench in the glasshouse, and the flowering trial was designed as a randomized block design across four benches within the flowering zone. Replicate numbers for each experiment are described below.

Experiment 1: The effect of root stock age on grafting success was tested using the highest-yielding, reliably performing genotype, THC7, as a rootstock and the low-yielding, high-CBDA genotype, CBD1, as a scion. The rootstock clones were cut from the donor mother plants successively over four timepoints so that on the day of grafting, they would be 10, 7, 4, and 0 days old. Six rootstocks were cultivated for each treatment. Rootstocks from days 10, 7, and 4 were cloned into coco-peat plugs and placed into a growth cabinet as previously described.

For grafting rootstocks age 4–10 days old, all equipment was cleaned with 70% PA before the procedure. A clone with developing roots was removed from the growth cabinet and laid horizontally on a cutting board. The leaf bunch at the top of the stem was excised with a scalpel to leave a 10 cm length of stem (still implanted in the propagation plug). The stem and propagation plug were returned to an upright position, and the scion was prepared. The scion was cut freshly from a CBD1 mother plant as a 15 cm section. All leaves up the sides of the stem were removed with secateurs, retaining the leaf bunch at the top. The stem was then cut with a scalpel to leave a length of approximately 10 cm (Figure 1C). The leaf bunch was trimmed to the height of the smallest developing leaf to minimize water loss, and the bottom 1 cm of the stem was slightly shaved on two opposite sides. A 1 cm incision was made vertically into the rootstock stem, and the scion was slid into place (cleft graft) and secured with a 3.3 mm recycled-plastic grafting clip (PT8 3.3, Royal Brinkman).

The day 0 treatment involved cutting fresh clonal stem sections from THC7 mother plants and directly grafting a fresh CBD1 scion (see method below).



**Figure 1.** Grafting methodology. (A) Two stems were cut from donor mother plants. An example is shown in A. One stem to form the scion and the other the rootstock. (B) The top leaf bunch was retained on the scion stem, it was trimmed then all other leaves were removed. (C) The rootstock stem was cut with a scalpel at a slight diagonal angle across a node and the 1 cm area of stem around the node is gently scraped with the scalpel. The top of the stem is cut to result in a 10 cm length section. (D) The scion stem is also cut to a 10 cm section using a scalpel and opposite sides of the stem are shaved to form a pencil shape. (E) A 1 cm incision is made into the top of the rootstock stem section. (F) The scion is slotted into the stem section, the stem surrounding the union is gently wiped with a tissue imbued with 70% ethanol, and the union is secured using a silicone grafting clip. (G) Grafted clones are placed in a propagation dome at 100% humidity. (H) Immediately after grafting, the plants will show considerable wilting \*. (I) Forty eight hours after grafting the plants have regained turgor \*. \* Plants were only removed from the propagation domes for the purpose of photography.

## 2.2. Single Step Grafting Method

A printable user methodology is also available in Supplementary.

All equipment was sterilized using 70% iso-propyl alcohol (PA).

**Rootstock preparation.** A rootstock stem (THC7, 8 or 9) was freshly cut from the mother, laid on a cutting board, and all leaves up the sides of the stem were removed with secateurs (Figure 1A,B). The leaf bunch at the top of the stem was excised approximately 1 cm below the lowest leaf with a scalpel, to leave a 10 cm stem section (Figure 1C). The bottom 1 cm of the stem, from which the roots would form, was lightly scraped with a scalpel. A vertical incision was made centrally down from the top of the stem, where the scion would connect, to a length of approximately 1 cm with a scalpel (Figure 1E).

A scion approximately 15 cm in length was freshly cut from a CBD1 or THC2 mother plant (Figure 1A,B). All leaves except the top-most bunch were removed, and the remaining bunch was trimmed to the length of the youngest emerging leaf to limit water loss (Figure 1D). The area of the scion and rootstock that was to form the union was lightly wiped with a tissue soaked with 70% PA. The base of the scion stem was slightly shaved on two opposite sides using a scalpel (Figure 1D). The scion was then slid into the incision in the rootstock stem, and a recycled-plastic grafting clip was used to hold the union. A 3.3 mm grafting clip was used (PT8 3.3 mm, Royal Brinkman, <https://www.royalbrinkman.com> accessed on 20 March 2022) (Figure 1F).

The bottom 1 cm of the rootstock stem was dipped in hormone gel (Clonex Purple, Yates, DuluxGroup, Australia) and then placed in propagation plug (Eazyplug, The Netherlands). Grafted clones were placed in the propagation domes which were sprayed with water and maintained at a humidity of ~100% for 7 days (Figure 1G). Significant wilting occurs immediately after single-step grafting (Figure 1H), and an experienced medicinal Cannabis grower may assume the method has failed. The grafts recover from the wilting but may take up to four days post-grafting to resume a healthy appearance (Figure 1I).

Over the remaining 7 days, the humidity was allowed to progressively decrease until clones with developed roots could be potted out and enter the main glasshouse area (Table 2).

**Table 2.** Survival of CBD1 scions grafted to THC7 rootstocks of different ages.

	Rootstock Age at Grafting (Days)	Grafts Taken	Transplanted	% Survival
Experiment 1:	10	6	2	33.3
	7	6	5	83.3
	4	6	5	83.3
Experiment 2:	0	6	6	100
	0	20	20	100

Experiment 3: Seven high THCA accumulating lines (Table 1), were used as rootstocks for CBD1 scions utilizing the fresh-on-fresh (day 0) grafting approach (as previously described) and grown for an extended vegetative period of 29 days as a fully randomized trial on a single bench (N = 5–6). The height and fresh weight of the grafted plants was recorded at the end of the trial.

Experiment 4: Two genotypes, THC8 and THC9, were selected as the rootstocks for CBD1 and THC2 scions based on results from Experiment 3. Plants were cultivated as described above and followed the standard production schedule for flowering plants (described above). Eight replicates of all controls (CBD1, THC9, 2, and 8) and grafts THC9r\_2s and THC9r\_CBD1s were included, but survival of THC8 rootstock grafts was lower, so 7 replicates of THC8r\_CBD1s and 5 replicates of THC8r\_2s were included. During vegetative growth, the trial followed a fully randomized design on a single bench, but when plants transferred to flowering, a randomized block design was employed to evenly distribute (as much as possible) the replicate plants across the four benches in the flowering area. Bamboo canes and ties were used to support the flowering plants. Plant height was measured every two weeks, and the morphological measures were made on the main stem and six longest side branches per plant when the plants had reached maturity at 76 day after cloning (DAC) 76. Harvest was carried out on 89–91 DAC.

### 2.3. Harvest Method

Plants were excised at the base, and then, the whole plant was weighed. The large fan leaves were removed, and the flowers were manually stripped from the stem and trimmed using a mechanical trimmer (TrimPro ROTOR, <https://www.trimpro.com>, accessed on 20 March 2022). The trimmed flowers were re-weighed (flower fresh weight), and a subsample (approximately 50 g) was also weighed into a foil tray. The subsamples were

dried in a dedicated drying room at 21 °C and 50% humidity until no further reduction in weight was observed (9 days). The subsamples were then re-weighed; the percent biomass and the total flower dry weight ( $\text{g plant}^{-1}$ ) were calculated.

**Root Area:** After the plants were harvested, four replicates (one from each bench) from each control/graft were randomly selected. They were gathered into their replicate sets and turned out of their pots, upside down, on a tarpaulin. Photographs were taken where the roots had gathered in the pot base. The photos were edited in Photoshop (Photoshop 22.5.1. Adobe ©, San Jose, CA, USA) to remove any perlite pieces. They were then opened in image analysis software, Image J [31,32], and a scale was defined from a plant tag of defined length that was included in each photograph. The image was converted to 8-bit black and white images, and then, the threshold was adjusted to a red-black image. A circular area that covered the bottom of the pot was drawn for each replicate, and the area of roots in mm was calculated in Image J [31,32].

#### 2.4. Cannabinoid Quantification

Four biological replicates (one from each bench) from the four graft types (THC8r\_CBD1s, THC9r\_CBD1s, THC8r\_2s, and THC9r\_2s) and their respective non-grafted varieties, CBD1 and THC2, were analysed for the concentration of 17 cannabinoids according to the method described by Hewavitharana et al. [33].

Three florets were randomly removed from the dried subsample flower material from each individual plant. From this, a further 0.1 g subsample was ground to a fine powder. Cannabinoids were extracted in 100% ethanol using sonication (SONICLEAN, Soniclean®, Dudley Park, SA, Australia) at 50/60 Hz. The ethanolic extract was analysed using High Performance Liquid Chromatography coupled to mass spectrometry (HPLC-MS, Agilent Technologies, Santa Clara, CA, USA). Separation was achieved using a reversed phase column (Agilent Poroshell, Agilent Technologies, Santa Clara, CA, USA) and methanol-water-acetonitrile mobile phase containing 0.1% formic acid (*v/v*). Cannabinoid peaks were identified according to their molar masses and quantified by calibration against known concentrations of commercially available cannabinoid standards. The method was validated in terms of detection and quantification limits, repeatability, and recoveries for all 17 cannabinoids before being used for quantification of cannabinoids in this study.

The total yield ( $\text{mg plant}^{-1}$ ) of each cannabinoid was calculated as


$$((\% \text{Cannabinoid}/100) \times \text{Total flower DW g}) \times 1000 = \text{mg cannabinoid plant}^{-1} \quad (1)$$

All graphics and statistical analyses were performed in R 3.1 [34].

### 3. Results

#### 3.1. Rootstock Age

Scions grafted to the 10-day old rootstock showed the lowest rate of survival, and the freshly cut scions grafted to a freshly cut stem piece showed the highest survival rate (Table 2). After an extended period of vegetative growth, the scions grafted to either 4- or 7-day old scions were significantly taller than those grafted to a freshly cut (day 0) stem piece, but there were no significant differences in fresh weight (Figure 2). As the fresh-on-fresh approach would require the lowest cultivation time and resources, we sought to repeat the high success rate achieved in the first experiment. In the second experiment, a 100% success rate was achieved with the fresh-on-fresh approach (Table 2). This method was used for the remaining experiments.



**Figure 2.** Stem length and scion weight after grafting. N = 5–6 except for 10 day old root stocks in which only 2 survived, so no standard error bar is included.

### 3.2. Rootstock Selection

As there is no method for grafting of medicinal Cannabis published in the scientific literature, we sought to determine whether phenotypic variation could be induced with different rootstocks. Eight different lines, including the two target scions, were included in our experiment (Table 1). CBD1 scions were grafted to every other rootstock and then grown over an extended vegetative growth period. Significant differences between graft combinations were observed. Two rootstocks, THC3 and THC8, resulted in significantly shorter plants than the control CBD1 plants (Table 3). The THC9 rootstock were the heaviest plants and were significantly heavier than when THC7 and 8 were used as rootstocks (Table 3). A strong correlation,  $R = 0.96$ , was observed between the height of the grafted plants and the maximum height observed from mature flowering plants of each line from



an earlier trial (Supplementary Figure S1). From these findings, THC9 and THC8 were selected as candidate rootstocks.

**Table 3.** Height (mm) and total above ground fresh weight (FW) (g) of CBD1 plants and CBD1 scions grafted to seven different rootstocks. N = 5–6  $\pm$  standard error. Different letters denote significant differences between genotypes/grafs (Tukey HSD test,  $p \leq 0.05$ ).

Genotype	Maximum Height (mm)	Above Ground FW (g)
CBD1	445.83 $\pm$ 7.79a	139 $\pm$ 4.0abc
THC9r_CBD1s	430.83 $\pm$ 8.31ab	152 $\pm$ 6.0c
THC1r_CBD1s	445.83 $\pm$ 2.71ab	127 $\pm$ 8.0abc
THC2r_CBD1s	447.00 $\pm$ 20.8ab	129 $\pm$ 10.0abc
THC3r_CBD1s	426.67 $\pm$ 7.15bc	134 $\pm$ 6.0abc
THC6r_CBD1s	430.83 $\pm$ 7.46ab	143 $\pm$ 6.0abc
THC7r_CBD1s	442.50 $\pm$ 8.24ab	132 $\pm$ 5.0ab
THC8r_CBD1s	422.00 $\pm$ 7.52bc	132 $\pm$ 6.0ab

### 3.3. Impact of Grafting on Flowering Plant Performance


Plant height was measured every two weeks from the start of vegetative growth. The THC8r\_CBD1s grafts were significantly shorter than either the CBD1 plants or the other graft type, THC9r\_CBD1s, once maximum height was reached (Figure 3A). The same significant height reduction was not observed in THC2 scions grafted to the THC8 rootstock (THC8r\_2s), but this graft was still the shortest (Figure 3B).

Stem morphology was altered by grafting in both scions. In CBD1 scions, grafting onto the THC8 rootstock resulted in fewer nodes per branch, longer internodes between inflorescences on the branches, and reduced total number of inflorescences (nodes on branches + the main stem) (Table 4).

**Table 4.** Stem morphology of control genotypes and grafted scions. Branch lengths, nodes per branch, and internode lengths are the average values from the 6 branches measured. N = 4,  $\pm$  = SE. Letters after SE denote significant differences between genotypes/grafs (Tukey HSD,  $p \leq 0.05$ ).

Genotype/Graft	Total Branch Number	Branch Length (mm)	Nodes per Branch	Internode Length (mm)	Inflorescence Number
CBD1	8.875 $\pm$ 0.31a	243.54 $\pm$ 6.40a	5.08 $\pm$ 0.06a	49.70 $\pm$ 1.44a	30.50 $\pm$ 0.35a
THC9r_CBD1s	8.50 $\pm$ 0.29a	255.10 $\pm$ 11.78a	4.90 $\pm$ 0.25ab	55.28 $\pm$ 1.35ab	29.38 $\pm$ 1.52ab
THC8r_CBD1s	8.00 $\pm$ 0.00a	229.27 $\pm$ 1.39a	4.29 $\pm$ 0.15b	57.95 $\pm$ 1.87b	25.75 $\pm$ 0.92b
THC2	12.625 $\pm$ 0.63a	521.15 $\pm$ 38.42ab	6.35 $\pm$ 0.30ab	85.56 $\pm$ 2.72a	38.13 $\pm$ 1.80ab
THC9r_2s	14.25 $\pm$ 0.32a	566.46 $\pm$ 23.47c	7.75 $\pm$ 0.12c	74.41 $\pm$ 2.80b	46.50 $\pm$ 0.74c
THC8r_2s	14.25 $\pm$ 0.48a	470.63 $\pm$ 21.76b	6.63 $\pm$ 0.28b	72.40 $\pm$ 3.09b	39.75 $\pm$ 1.65b

The THC2 scions grafted to THC8 rootstocks (THC8r\_2s) showed reduced internode lengths compared to THC2, but no other significant differences were observed between this graft and the non-grafted THC2 plants (Table 4). The combination of the THC9 rootstock and the THC2 scion (THC9r\_2s) produced a number of favourable morphological differences. Specifically, in THC9r\_2s plants, the branches were significantly longer, but the internode lengths on the branches were reduced, and there were more nodes per branch (Table 4). There were on average 22% more inflorescences on the THC9r\_2s grafted plants than in the non-grafted THC2 controls (Table 4).




**Figure 3.** (A) Height of ungrafted CBD1 plants and grafted CBD1 scions on THC9 and THC8 rootstocks. (B) Height of ungrafted THC2 plants and grafted THC2 scions on THC9 and THC8 rootstocks. N = 5–8 and Letters above the bars denote significant differences (Tukey HSD,  $p \leq 0.05$ ), nsd = no significant difference.

Photographs of the controls and respective grafts are shown in Figure 4. The shortened stature of THC8r\_CBD1s can be seen (Figure 4B), and both THC2 grafts appear “bushier” compared to the control which is probably the result of the reduced internode length observed in both graft types (Figure 4C,D).

The dry flower yield data showed that THC2 and the two THC2 grafted plants produced the highest yields of all plants tested; the lowest was the THC8r\_CBD1s graft, and all others were similar (Figure 5A). The THC9r\_2s graft showed a significant increase in yield of 19% over the non-grafted THC2 plants which is consistent with the observation of a 22% increase in inflorescence number (Table 4). The average yield of THC9r\_2s was  $86.9 \text{ g plant}^{-1}$  compared to  $73 \text{ g plant}^{-1}$  for THC2 (Figure 5A).


It was also interesting to observe the size of the error bars on Figure 5A; the standard deviation of THC2 yield was  $\pm 10.9$  compared to  $\pm 1.4$  for THC9r\_2s. This was seen as important because it shows two things: firstly, the problem of inconsistency encountered with the THC2 variety, and secondly, that this inconsistency is the result of root development, which could be bypassed through grafting.



**Figure 4.** (A,B): Photograph of the ungrafted CBD1 plants next to the grafted THC9r\_CBD1s and THC8r\_CBD1s. (C,D): The THC2 ungrafted plants next to the grafted THC8r\_2s and THC9r\_CBD2s. Plants were selected based on being closest to the median value for height.

The genotype with the largest root area was CBD1, and the genotype with the smallest was THC2 (Figure 5). The two grafts with the largest root area were THC8r\_2s and THC9r\_2s, i.e., both rootstocks with the THC2 scions. These root areas were both significantly larger than non-grafted THC2. Furthermore, THC9r\_2s was significantly larger than non-grafted THC9 with a 26% increase in root area of the grafts. Conversely, both rootstocks of CBD1 scions were significantly smaller than that of CBD1 but similar to their non-grafted controls (THC8 and THC9).

The pattern between Figure 5A showing the flower DW and Figure 5B, root area, demonstrated that with the exception of the two lines selected for improvement (CBD1 and THC2), the trend was similar, indicating plants with larger roots also had bigger yields (and vice versa).



**Figure 5.** A and B: Flower yield (g DW plant<sup>-1</sup>) (A) and root area (B) from control and grafted plants. Letters above the bars denote significant differences (Tukey HSD,  $p \leq 0.05$ ).

### 3.4. Cannabinoid Composition

Seventeen cannabinoids were quantified, but two, d8-THC and CBL, were undetectable in our samples (data not shown). The concentration ( $\mu\text{g g}^{-1}$  DW) of each detectable cannabinoid for each graft type and the non-grafted plants is shown in Table 5. In THC8r\_CBD1s grafts the concentration of the target cannabinoid, CBDA, was significantly increased to 8.6% DW compared to 7.6% DW in the non-grafted CBD1 plants (Table 5). The concentration of cannabinol (CBN) was also significantly increased in this graft-type, and the THC9r\_CBD1s grafts had significantly less THC than the non-grafted plants (Table 5). In the THC2 grafts, only a single difference in the cannabinoid concentration was observed, which was a significant increase in cannabicyclic acid (CBLA) in both graft types (THC9r\_2s and THC8r\_2s) (Table 5). A trend towards higher THCA concentration in both THC2 graft types was also observed.

Overall, few changes in the concentration of cannabinoids were observed following grafting, even in the high CBD scions grafted to a high THC rootstock.

The concentration of cannabinoids was combined with the yield data for the analysed plants to calculate the yield (mg Plant<sup>-1</sup>) of each cannabinoid (Table 6).

In THC8r\_CBD1s, the concentrations of the two decarboxylated cannabinoids, CBD and THC, were significantly lower compared to CBD1 plants. The total yield of THCA in the THC9r\_2s was 13.6 g plant<sup>-1</sup> (13,622 mg) compared to 8.2 g plant<sup>-1</sup> (8158.9 mg) for THC2, an increase of 67% over the non-grafted plants (Table 6).

**Table 5.** Concentration of cannabinoids ( $\mu\text{g g DW}$ ) in control genotypes and grafted scions.  $N = 3\text{--}4$   $\pm$  SE. Values shown in bold and letters below them denote significant differences between genotypes/grafts (Tukey HSD,  $p \leq 0.05$ ).

Genotype/Graft	CBD1	THC9r_CBD1s	THC8r_CBD1s	THC2	THC9r_2s	THC8r_2s
<b>CBDV</b>	8.75 $\pm$ 0.44	7.95 $\pm$ 0.43	7.80 $\pm$ 0.53	0.70 $\pm$ 0.35	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>CBDVA</b>	282.98 $\pm$ 12.38	235.04 $\pm$ 16.57	283.18 $\pm$ 6.36	14.84 $\pm$ 8.84	28.08 $\pm$ 3.38	4.97 $\pm$ 3.07
<b>CBG</b>	274.59 $\pm$ 9.30	235.98 $\pm$ 8.93	276.44 $\pm$ 11.48	413.99 $\pm$ 28.78	403.96 $\pm$ 14.66	375.80 $\pm$ 10.37
<b>CBGA</b>	618.17 $\pm$ 62.00	437.92 $\pm$ 43.89	510.94 $\pm$ 27.16	3507.16 $\pm$ 132.40	3302.13 $\pm$ 76.82	3158.43 $\pm$ 133.87
<b>THCV</b>	2.99 $\pm$ 0.45	3.10 $\pm$ 0.13	2.91 $\pm$ 0.19	18.21 $\pm$ 4.87	16.67 $\pm$ 1.49	14.48 $\pm$ 1.28
<b>THCVA</b>	21.41 $\pm$ 4.85	19.47 $\pm$ 1.93	22.12 $\pm$ 7.04	1497.00 $\pm$ 156.43	1179.77 $\pm$ 526.97	1753.37 $\pm$ 142.74
<b>CBN</b>	<b>1.45</b> $\pm$ 0.66 <b>a</b>	<b>2.53</b> $\pm$ 0.83 <b>a</b>	<b>5.99</b> $\pm$ 0.22 <b>b</b>	4.63 $\pm$ 1.33	5.14 $\pm$ 0.50	5.20 $\pm$ 0.82
<b>CBNA</b>	26.99 $\pm$ 5.33	3.41 $\pm$ 2.21	22.65 $\pm$ 15.62	376.29 $\pm$ 11.48	366.12 $\pm$ 5.52	334.24 $\pm$ 19.28
<b>CBC</b>	192.75 $\pm$ 5.50	183.57 $\pm$ 4.75	178.26 $\pm$ 12.92	62.70 $\pm$ 23.60	53.27 $\pm$ 5.72	45.88 $\pm$ 5.14
<b>CBCA</b>	2656.59 $\pm$ 173.23	2421.79 $\pm$ 208.73	3027.04 $\pm$ 42.10	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>CBLA</b>	121.67 $\pm$ 18.89	507.50 $\pm$ 259.57	355.98 $\pm$ 128.22	<b>852.97</b> $\pm$ 35.81 <b>a</b>	<b>1162.57</b> $\pm$ 62.82 <b>b</b>	<b>1178.88</b> $\pm$ 31.66 <b>b</b>
<b>CBD</b>	2127.27 $\pm$ 19.89	2317.93 $\pm$ 110.48	1981.99 $\pm$ 125.22	21.47 $\pm$ 12.00	41.20 $\pm$ 1.84	38.73 $\pm$ 0.63
<b>CBDA</b>	<b>76,504.48</b> $\pm$ 1384.01 <b>a</b>	<b>77,459.11</b> $\pm$ 2784.75 <b>a</b>	<b>86,119.56</b> $\pm$ 1382.27 <b>b</b>	335.06 $\pm$ 39.42	302.28 $\pm$ 56.11	216.29 $\pm$ 7.30
<b>THC</b>	<b>526.71</b> $\pm$ 4.95 <b>a</b>	<b>476.23</b> $\pm$ 10.48 <b>b</b>	<b>491.86</b> $\pm$ 14.58 <b>ab</b>	2455.09 $\pm$ 642.03	2602.35 $\pm$ 239.35	2233.05 $\pm$ 166.03
<b>THCA</b>	3433.15 $\pm$ 216.20	3064.04 $\pm$ 184.21	3629.15 $\pm$ 209.63	138,838.11 $\pm$ 2522.18	149,386.51 $\pm$ 6396.65	144,570.38 $\pm$ 7562.30

**Table 6.** Total yield of cannabinoids (mg Plant<sup>-1</sup>) in control genotypes and grafted scions. N = 3–4 +/- = SE. Values shown in bold and letters below them denote significant differences between genotypes/grafts (Tukey HSD,  $p \leq 0.05$ ).

Genotype/Graft	CBD1	THC9r_CBD1s	THC8r_CBD1s	THC2	THC9r_2s	THC8r_2s
CBDV	0.30 +/- 0.02	0.26 +/- 0.02	0.19 +/- 0.02	0.04 +/- 0.02	0.00 +/- 0.00	0.00 +/- 0.00
CBDVA	9.78 +/- 0.52	7.83 +/- 0.80	7.04 +/- 0.40	0.80 +/- 0.46	2.60 +/- 0.46	0.40 +/- 0.26
CBG	9.48 +/- 0.37	7.96 +/- 1.04	6.90 +/- 0.56	<b>24.49 +/- 3.37a</b>	<b>36.94 +/- 3.40b</b>	<b>28.87 +/- 1.98ab</b>
CBGA	21.53 +/- 2.63	15.28 +/- 3.62	12.72 +/- 1.00	206.61 +/- 21.78	300.81 +/- 20.83	244.58 +/- 25.79
THCV	0.10 +/- 0.01	0.10 +/- 0.01	0.07 +/- 0.01	1.10 +/- 0.37	1.53 +/- 0.20	1.14 +/- 0.19
THCVA	0.73 +/- 0.16	0.66 +/- 0.10	0.57 +/- 0.19	88.89 +/- 15.25	100.75 +/- 43.89	136.25 +/- 18.49
CBN	0.05 +/- 0.02	0.08 +/- 0.02	0.15 +/- 0.01	0.26 +/- 0.06	0.46 +/- 0.04	0.40 +/- 0.06
CBNA	0.93 +/- 0.18	0.14 +/- 0.11	0.52 +/- 0.35	22.00 +/- 1.19	33.27 +/- 1.74	25.61 +/- 1.86
CBC	6.66 +/- 0.30	6.19 +/- 0.81	4.42 +/- 0.36	3.84 +/- 1.69	4.86 +/- 0.61	3.61 +/- 0.67
CBCA	92.52 +/- 10.02	80.52 +/- 8.53	75.55 +/- 5.28	0.00 +/- 0.00	0.00 +/- 0.00	0.00 +/- 0.00
CBLA	4.32 +/- 0.94	15.73 +/- 7.07	9.25 +/- 3.84	30.30 +/- 14.87	105.87 +/- 8.73	91.42 +/- 9.64
CBD	<b>73.69 +/- 3.90a</b>	<b>77.37 +/- 7.71a</b>	<b>49.11 +/- 3.34b</b>	1.25 +/- 0.70	3.74 +/- 0.25	3.00 +/- 0.29
CBDA	2659.30 +/- 196.78	2608.15 +/- 324.99	2148.84 +/- 148.97	19.78 +/- 2.99	27.28 +/- 4.59	16.59 +/- 1.08
THC	<b>18.24 +/- 0.92a</b>	<b>15.96 +/- 1.72ab</b>	<b>12.23 +/- 0.72b</b>	148.33 +/- 48.56	237.38 +/- 27.29	173.70 +/- 24.40
THCA	119.99 +/- 13.31	101.00 +/- 5.59	90.17 +/- 6.11	<b>8158.95 +/- 703.47a</b>	<b>13,622.48 +/- 1132.07b</b>	<b>11,036.36 +/- 554.63ab</b>

#### 4. Discussion

We have developed a grafting methodology for medicinal Cannabis that requires only a single cultivation step to connect a freshly cut donor scion to a freshly cut stem that will become the rootstock over only fourteen days. The method does not require any additional days of cultivation away from the usual propagation schedule and so does not reduce yield by increasing cultivation time. However, extra time is required to make the grafts compared to standard cloning. We estimate that grafting is three-fold slower than standard cloning. Another consideration is that mother plants for both the rootstock and scion would need to be maintained which increases labour demands and spacing requirements within the cultivation facility.

However, the potential benefits of grafting in medicinal Cannabis may extend beyond immediate yield advantages, as this method has been used in other crops to identify hormones, proteins, and RNAs that result in long-distance communication systems within the plant [18,19].

A prominent example are strigolactones, root-derived, actively transported [35] phytohormones with profound effects on shoot architecture [36]. While having multiple below-ground and aboveground effects, including plant microbe interactions, strigolactones are best characterized for their negative regulation of lateral branching in response to nutrient availability, which is achieved in a complex interplay with other phytohormones [37]. Strigolactones remained long elusive and were largely discovered and characterized through grafting experiments with biosynthesis and signal perception mutants in petunia (DAD mutants—decreased apical dominance), pea (RMS mutants—ramosus), and Arabidopsis (MAX mutants—more axillary branching) [38]. Strigolactone biosynthesis mutants showed a strong increased branching phenotype, which could be rescued by grafting mutant scions on wild type rootstock, which would then supply the signal. Contrastingly, strigolactone perception mutants could not be rescued via grafting.

It is likely that the branching and stunting phenotypes observed in our grafting experiments could at least in part be explained by differences between scion and rootstock in respect to strigolactone biosynthesis, perception, and or interaction with other phytohormones.

As a new crop to Australia, and one that produces medical products regulated by the Therapeutic Goods Act, there are currently no chemicals registered for use for the control of pests and diseases in medicinal Cannabis. Growers are therefore very vulnerable to outbreaks. Grafting may also be used as a scientific tool to identify novel methods of crop protection.

The main use of grafting in annual horticultural crops is for disease resistance to soil borne pathogens such as fusarium [39] and verticillium [40]. However, (currently) the main threats to medicinal Cannabis production are from foliar and flower pathogens, specifically botrytis (bud rot) and Golovinomyces Sp. (causing powdery mildew) [41]. Long-distance transport/signalling mechanisms exist between roots and the aerial plant part, and these could provide a mechanism for inducing adaptations in the scion. For example, it has been demonstrated that grafting a powdery mildew (PM) susceptible scion on to a PM resistant rootstock reduced foliar infection in cucumber [42]. The mechanism by which this occurs may have been via long-distance transport or through alteration of the metabolic profile of the scion [43]. Differences in the expression of defence related transcripts or the proteome have also been observed in response to grafting in “Gala” apples and cucumber, respectively [43,44], and grafting may also promote induced systemic resistance by altering rhizobacterial populations [45].

These examples raise the possibility that grafting could induce adaptive or resistance traits to foliar/floral pathogens into medicinal Cannabis directly or be a means to discover new pathways that can be manipulated to increase plant defences without chemicals.

The capacity of medicinal Cannabis to produce viable roots from defoliated, grafted, stem sections, with a high rate of success (>90% for THC9 rootstock grafts), in just 14 days, is remarkable. Indeed, we have observed that the scion and rootstock stem fuse within 72 h (data not shown). Willow (*Salix* Sp) also shows high regenerative rates and “willow

water" extracted from the bark is used to promote root formation in other species, the active metabolite being salicylic acid [46]. Characterisation of the cannabinoids and terpenes of *Cannabis* has been the subject of many publications [3,6,47–50], but the characterization and quantification of hormones has not; the underlying mechanism(s) behind this pronounced regenerative capacity remain to be discovered.

The presented method was capable of reducing height and changing stem morphology. Yields were also increased through increased flower biomass in one of our graft combinations. The outcomes from the two rootstocks used in our flowering trial were scion specific; one rootstock reduced plant height in one of the target scions but not the other, and another rootstock increased yield in one scion but not the other. The specificity of the rootstock–scion relationship has been previously reported in multiple crops [17]. The poorer survival rate of clones grafted to the THC8 rootstock also shows that, as with other crops, all rootstocks are not equal, and experimentation is required to identify optimal combinations.

The rationale for using THC2 as a scion was that it showed variable root development during cloning which resulted in an unacceptably high failure rate (for commercial production). By grafting THC2 to THC9, this problem was ameliorated. However, the improvement that was observed in this graft combination cannot be explained by improved root area alone because the root area of THC8r\_2s was also larger than non-grafted THC2, but there was no biomass yield advantage. Furthermore, the THC9r\_CBD1s grafts had a rootstock less than half the area of CBD1 but showed no loss of yield, and the THC2 plants had the smallest root area of all lines but still produced exceptionally high yields. These findings show that a large root area is not necessary to produce high yields (indeed it can indicate the opposite). Why THC2 is impaired in root development has not been uncovered by this study but is not the result of inadequate signalling or transport/partitioning of carbon from the source organs, as both rootstocks grafted to this scion produced a root area that exceeded that of the non-grafted controls.

Overall, few changes in the concentration of cannabinoids were observed in the grafted scions. The main difference was that the concentration of CBDA was increased in one of the CBD1 grafted lines; however, as the biomass yield of this line was lower, the final yield of CBDA was not improved. A negative relationship between CBDA and biomass yield has been previously reported [51]. In this cited example, the treatment applied (P fertilization) increased biomass yield but decreased CBDA concentration which the authors attributed to a diluting effect [51]. Our observation may be the opposite response; a concentrating effect on CBDA from reduced biomass.

Cannabinol (CBN) was found in significantly higher quantities in one CBD1 graft type. This cannabinoid is a breakdown product from the degradation of THC, which is reportedly linked to aged, stored *Cannabis* [52]. Both graft combinations of THC2 produced significantly higher concentrations of CBLA, which is again considered to be a breakdown product formed during storage or through exposure to environmental conditions. As all of our samples were stored and processed together, it is unclear why there should be increased concentrations of these cannabinoids. It is possible that the grafting process may have accelerated senescence, so the flowers were more mature at harvest. However, no differences in the % dry weight of the flowers or visual symptoms of accelerated maturity were observed.

The minimum number of changes induced by grafting suggests that the root has little influence on the cannabinoid concentrations, but through its effect on flower biomass, the grafting method presented can increase yields of THCA.

## 5. Conclusions

We have developed a new grafting methodology for medicinal *Cannabis* that does not require seed germination or prior cultivation of a rootstock before grafting takes place. The method can alter stem morphology and, in the right combination, improve biomass and THCA yields. The presented method may provide a useful scientific tool for the discovery of root-stem interactions and signalling pathways.



**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/agronomy12040852/s1>, One-step method for grafting medicinal Cannabis. Supplementary Figure S1: Spearman's rank correlation between rootstock mature plant height and grafted CBD1 scion height.

**Author Contributions:** Conceptualization, S.J.P. and N.J.M.; methodology, S.J.P., A.K.H., software, S.J.P., A.T.; validation, S.J.P., A.K.H.; formal analysis, S.J.P., A.K.H., R.A.H.; investigation, S.J.P., A.K.H., T.J.P., N.J.M., A.T.; resources, T.K.; writing—original draft preparation, S.J.P.; writing—review and editing, T.K., D.H.; visualization, S.J.P., A.T.; supervision, S.J.P., T.K., D.H.; funding acquisition, D.H., T.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This project received grant funding from the Australian Government via the Department of Industry, Science, Energy and Resources, as part of the Cooperative Research Centres Project (CRC-P) program—Round 7—Growing the medicinal Cannabis industry—precision farming to pharmaceuticals.

**Data Availability Statement:** Data is contained within the article and Supplementary Material.

**Acknowledgments:** We want to thank Cann Group Limited, lead industry partner on the CRC-P, for their valuable input and for providing proprietary germplasm for this research.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Parliament of Australia, Narcotic Drug Amendment Bill 2016. Available online: [https://www.aph.gov.au/Parliamentary\\_Business/Bills\\_Legislation/Bills\\_Search\\_Results/Result?bId=r5609](https://www.aph.gov.au/Parliamentary_Business/Bills_Legislation/Bills_Search_Results/Result?bId=r5609) (accessed on 20 March 2022).
2. Australian Government Department of Health Office of Drug Control. Available online: <https://www.odc.gov.au/summary-licences-granted> (accessed on 20 March 2022).
3. Flores-Sanchez, I.J.; Verpoorte, R. Secondary Metabolism in Cannabis. *Phytochem. Rev.* **2008**, *7*, 615–639. [[CrossRef](#)]
4. Alger, B.E. Getting high on the endocannabinoid system. *Cerebrum* **2013**, *2013*, 14.
5. Welling, M.T.; Liu, L.; Raymond, C.A.; Ansari, O.; King, G.J. Developmental Plasticity of the Major Alkyl Cannabinoid Chemotypes in a Diverse Cannabis Genetic Resource Collection. *Front. Plant Sci.* **2018**, *9*, 1510. [[CrossRef](#)] [[PubMed](#)]
6. Gulck, T.; Moller, B.L. Phytocannabinoids: Origins and Biosynthesis. *Trends Plant Sci.* **2020**, *25*, 985–1004. [[CrossRef](#)] [[PubMed](#)]
7. Anderson, L.L.; Heblinski, M.; Absalom, N.L.; Hawkins, N.A.; Bowen, M.T.; Benson, M.J.; Zhang, F.; Bahceci, D.; Doohan, P.T.; Chebib, M.; et al. Cannabigerolic acid, a major biosynthetic precursor molecule in Cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. *Br. J. Pharmacol.* **2021**, *178*, 4826–4841. [[CrossRef](#)] [[PubMed](#)]
8. Chandra, S.; Lata, H.; ElSohly, M.A.; Walker, L.A.; Potter, D. Cannabis cultivation: Methodological issues for obtaining medical-grade product. *Epilepsy Behav.* **2017**, *70*, 302–312. [[CrossRef](#)]
9. Mechoulam, R.; Ben-Shabat, S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of Cannabis. *Nat. Prod. Rep.* **1999**, *16*, 131–143. [[CrossRef](#)]
10. Hoch, E.; Friemel, C.; Schneider, M.; Pogarell, O.; Hasan, A.; Preuss, U.W. Efficacy and safety of medicinal Cannabis: Results of the CaPRis study. *Bundesgesundheitsblatt Gesundh. Gesundh.* **2019**, *62*, 825–829. [[CrossRef](#)]
11. Ali, S.; Scheffer, I.E.; Sadleir, L.G. Efficacy of cannabinoids in paediatric epilepsy. *Dev. Med. Child Neurol.* **2018**, *61*, 13. [[CrossRef](#)]
12. Blake, A.; Wan, B.A.; Malek, L.; DeAngelis, C.; Diaz, P.; Lao, N.; Chow, E.; O'Hearn, S. A selective review of medical Cannabis in cancer pain management. *Ann. Palliat. Med.* **2017**, *6*, S215–S222. [[CrossRef](#)]
13. Backer, R.; Schwinghamer, T.; Rosenbaum, P.; McCarty, V.; Bilodeau, S.E.; Lyu, D.; Ahmed, B.; Robinson, G.; Lefsrud, M.; Wilkins, O.; et al. Closing the Yield Gap for Cannabis: A Meta-Analysis of Factors Determining Cannabis Yield. *Front. Plant. Sci.* **2019**, *10*, 495. [[CrossRef](#)] [[PubMed](#)]
14. Measuring Yield. Cannabis Business Times. Available online: <https://www.cannabisbusinesstimes.com/article/measuring-yield/> (accessed on 6 October 2016).
15. Caulkins, J.P. *Estimated Cost of Production for Legalized Cannabis*; RAND Drug Policy Research Centre: Santa Monica, CA, USA, 2010.
16. Nawaz, M.A.; Imtiaz, M.; Kong, Q.; Cheng, F.; Ahmed, W.; Huang, Y.; Bie, Z. Grafting: A Technique to Modify Ion Accumulation in Horticultural Crops. *Front. Plant. Sci.* **2016**, *7*, 1457. [[CrossRef](#)] [[PubMed](#)]
17. Lee, J.-M.; Kubota, C.; Tsao, S.J.; Bie, Z.; Echevarria, P.H.; Morra, L.; Oda, M. Current status of vegetable grafting: Diffusion, grafting techniques, automation. *Sci. Hortic.* **2010**, *127*, 93–105. [[CrossRef](#)]
18. Thomas, H.R.; Frank, M.H. Connecting the pieces: Uncovering the molecular basis for long-distance communication through plant grafting. *New Phytol.* **2019**, *223*, 582–589. [[CrossRef](#)]
19. Melnyk, C.W.; Meyerowitz, E.M. Plant grafting. *Curr. Biol.* **2015**, *25*, R183–R188. [[CrossRef](#)] [[PubMed](#)]

20. Cervantes, J. *The Cannabis Encyclopedia: The Definitive Guide to Cultivation & Consumption of Medical Marijuana*; Van Patten Publishing: Vancouver, WA, USA, 2015.
21. Deloitte, A. Economics, Pty Ltd. Modelling the Cost of Medicinal Cannabis. Department of Health. Office of Drug Control. 2016. Available online: <https://www2.deloitte.com/content/dam/Deloitte/au/Documents/Economics/deloitte-au-modelling-cost-medicinal-cannabis-230916.pdf> (accessed on 20 March 2022).
22. Gorelick, J.; Bernstein, N. Chemical and Physical Elicitation for Enhanced Cannabinoid Production in Cannabis. In *Cannabis sativa L.—Botany and Biotechnology*; Chandra, S., Lata, H., ElSohly, M., Eds.; Springer: Cham, Switzerland, 2017. [CrossRef]
23. Saloner, A.; Bernstein, N. Nitrogen supply affects cannabinoid and terpenoid profile in medical Cannabis (*Cannabis sativa* L.). *Ind. Crop. Prod.* **2021**, *167*, 113516. [CrossRef]
24. Magagnini, G.; Grassi, G.; Kotiranta, S. The Effect of Light Spectrum on the Morphology and Cannabinoid Content of *Cannabis sativa* L. *Med. Cannabis Cannabinoids* **2018**, *1*, 19–27. [CrossRef]
25. Danziger, N.; Bernstein, N. Light matters: Effect of light spectra on cannabinoid profile and plant development of medical Cannabis (*Cannabis sativa* L.). *Ind. Crop. Prod.* **2021**, *164*, 113351. [CrossRef]
26. Namdar, D.; Charuvi, D.; Ajampura, V.; Mazuz, M.; Ion, A.; Kamara, I.; Koltai, H. LED lighting affects the composition and biological activity of Cannabis sativa secondary metabolites. *Ind. Crop. Prod.* **2019**, *132*, 177–185. [CrossRef]
27. Danziger, N.; Bernstein, N. Plant architecture manipulation increases cannabinoid standardization in ‘drug-type’ medical Cannabis. *Ind. Crop. Prod.* **2021**, *167*, 113528. [CrossRef]
28. Caplan, D.; Dixon, M.; Zheng, Y.B. Increasing Inflorescence Dry Weight and Cannabinoid Content in Medical Cannabis Using Controlled Drought Stress. *Hortscience* **2019**, *54*, 964–969. [CrossRef]
29. Toth, J.A.; Smart, L.B.; Smart, C.D.; Stack, G.M.; Carlson, C.H.; Philippe, G.; Rose, J.K.C. Limited effect of environmental stress on cannabinoid profiles in high-cannabidiol hemp (*Cannabis sativa* L.). *GCB Bioenergy* **2021**, *13*, 1666–1674. [CrossRef]
30. Westmoreland, F.M.; Kusuma, P.; Bugbee, B. Cannabis lighting: Decreasing blue photon fraction increases yield but efficacy is more important for cost effective production of cannabinoids. *PLoS ONE* **2021**, *16*, e0248988. [CrossRef] [PubMed]
31. Rueden, C.T.; Schindelin, J.; Hiner, M.C.; DeZonia, B.E.; Walter, A.E.; Arena, E.T.; Eliceiri, K.W. ImageJ2: ImageJ for the next generation of scientific image data. *BMC Bioinform.* **2017**, *18*, 529. [CrossRef] [PubMed]
32. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **2012**, *9*, 671–675. [CrossRef]
33. Hewavitharana, A.K.; Gloerfelt-Tarp, F.; Nolan, M.; Barkla, B.J.; Purdy, S.; Kretzschmar, T. Simultaneous Quantification of 17 Cannabinoids in Cannabis Inflorescence by Liquid Chromatography-Mass Spectrometry. *Separations* **2022**, *9*, 85. [CrossRef]
34. Team, R. *RStudio: Integrated Development for R*. RStudio; PBC: Boston, MA, USA, 2020.
35. Kretzschmar, T.; Kohlen, W.; Sasse, J.; Borghi, L.; Schlegel, M.; Bachelier, J.B.; Martinoia, E.; Bours, R.; Bouwmeester, H.J. A petunia ABC protein controls strigolactone-dependent symbiotic signalling and branching. *Nature* **2012**, *483*, 341–344. [CrossRef]
36. Gomez-Roldan, V.; Fermas, S.; Brewer, P.B.; Puech-Pagès, V.; Dun, E.A.; Pillot, J.-P.; Letisse, F.; Matusova, R.; Danoun, S.; Portais, J.-C.; et al. Strigolactone inhibition of shoot branching. *Nature* **2008**, *455*, 189–194. [CrossRef]
37. Mashiguchi, K.; Seto, Y.; Yamaguchi, S. Yamaguchi, Strigolactone biosynthesis, transport and perception. *Plant J.* **2021**, *105*, 335–350. [CrossRef]
38. Xie, X.N.; Yoneyama, K.; Yoneyama, K. The Strigolactone Story. *Annu. Rev. Phytopathol.* **2010**, *48*, 93–117. [CrossRef]
39. Bithell, S.L.; Condé, B.; Traynor, M.; Donald, E.C. Donald, Grafting for soilborne disease management in Australian vegetable production systems—A review. *Australas. Plant Pathol.* **2012**, *42*, 329–336. [CrossRef]
40. Devi, P.; Tymon, L.; Keinath, A. Miles, Progress in grafting watermelon to manage Verticillium wilt. *Plant Pathol.* **2021**, *70*, 767–777. [CrossRef]
41. Punja, Z.K.; Collyer, D.; Scott, C.; Lung, S.; Holmes, J.; Sutton, D. Pathogens and Molds Affecting Production and Quality of *Cannabis sativa* L. *Front. Plant Sci.* **2019**, *10*, 1120. [CrossRef]
42. Kousik, C.S.; Ikerd, J.L.; Hassell, R. Powdery mildew resistant cucurbit rootstocks confer tolerance to grafted susceptible watermelon scions. *Phytopathology* **2015**, *105*, 75.
43. Guan, W.J.; Zhao, X.; Hassell, R.; Thies, J. Defense Mechanisms Involved in Disease Resistance of Grafted Vegetables. *Hortscience* **2012**, *47*, 164–170. [CrossRef]
44. Jensen, P.J.; Rytter, J.; Detwiler, E.A.; Travis, J.W.; McNellis, T.W. Rootstock effects on gene expression patterns in apple tree scions. *Plant Mol. Biol.* **2003**, *53*, 493–511. [CrossRef] [PubMed]
45. van Loon, L.C. Plant responses to plant growth-promoting rhizobacteria. *Eur. J. Plant Pathol.* **2007**, *119*, 243–254. [CrossRef]
46. Wise, K.; Gill, H.; Selby-Pham, J. Willow bark extract and the biostimulant complex Root Nectar (R) increase propagation efficiency in chrysanthemum and lavender cuttings. *Sci. Hortic.* **2020**, *263*, 109108. [CrossRef]
47. Hemphill, J.K.; Turner, J.C.; Mahlberg, P.G. Cannabinoid Content of Individual Plant Organs from Different Geographical Strains of *Cannabis-Sativa*, L. *J. Nat. Prod.* **1980**, *43*, 112–122. [CrossRef]
48. Welling, M.T.; Liu, L.; Kretzschmar, T.; Mauleon, R.; Ansari, O.; King, G.J. An extreme-phenotype genome-wide association study identifies candidate cannabinoid pathway genes in Cannabis. *Sci. Rep.* **2020**, *10*, 1–14. [CrossRef]

49. Welling, M.T.; Liu, L.; Shapter, T.; Raymond, C.A.; King, G.J. Characterisation of cannabinoid composition in a diverse *Cannabis sativa* L. germplasm collection. *Euphytica* **2016**, *208*, 463–475. [[CrossRef](#)]
50. Sommano, S.R.; Chittasupho, C.; Ruksiriwanich, W.; Jantrawut, P. The Cannabis Terpenes. *Molecules* **2020**, *25*, 5792. [[CrossRef](#)] [[PubMed](#)]
51. Shiponi, S.; Bernstein, N. The Highs and Lows of P Supply in Medical Cannabis: Effects on Cannabinoids, the Ionome, and Morpho-Physiology. *Front. Plant. Sci.* **2021**, *12*, 657323. [[CrossRef](#)]
52. Andre, C.M.; Hausman, J.F.; Guerriero, G. Cannabis sativa: The Plant of the Thousand and One Molecules. *Front. Plant. Sci.* **2016**, *7*, 19. [[CrossRef](#)] [[PubMed](#)]